150 related articles for article (PubMed ID: 1312696)
1. High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors.
D'Amico D; Carbone D; Mitsudomi T; Nau M; Fedorko J; Russell E; Johnson B; Buchhagen D; Bodner S; Phelps R
Oncogene; 1992 Feb; 7(2):339-46. PubMed ID: 1312696
[TBL] [Abstract][Full Text] [Related]
2. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H
Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413
[TBL] [Abstract][Full Text] [Related]
3. Use of the single strand conformation polymorphism technique and PCR to detect p53 gene mutations in small cell lung cancer.
Hensel CH; Xiang RH; Sakaguchi AY; Naylor SL
Oncogene; 1991 Jun; 6(6):1067-71. PubMed ID: 1648702
[TBL] [Abstract][Full Text] [Related]
4. p53 mutations in human lung tumors.
Miller CW; Simon K; Aslo A; Kok K; Yokota J; Buys CH; Terada M; Koeffler HP
Cancer Res; 1992 Apr; 52(7):1695-8. PubMed ID: 1312896
[TBL] [Abstract][Full Text] [Related]
5. Alterations of the p53 gene are common and critical events for the maintenance of malignant phenotypes in small-cell lung carcinoma.
Sameshima Y; Matsuno Y; Hirohashi S; Shimosato Y; Mizoguchi H; Sugimura T; Terada M; Yokota J
Oncogene; 1992 Mar; 7(3):451-7. PubMed ID: 1312700
[TBL] [Abstract][Full Text] [Related]
6. Mutational spectrum of the p53 gene in human small-cell lung cancer and relationship to clinicopathological data.
Lohmann D; Pütz B; Reich U; Böhm J; Präuer H; Höfler H
Am J Pathol; 1993 Mar; 142(3):907-15. PubMed ID: 8384408
[TBL] [Abstract][Full Text] [Related]
7. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group.
Chiba I; Takahashi T; Nau MM; D'Amico D; Curiel DT; Mitsudomi T; Buchhagen DL; Carbone D; Piantadosi S; Koga H
Oncogene; 1990 Oct; 5(10):1603-10. PubMed ID: 1979160
[TBL] [Abstract][Full Text] [Related]
8. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
[TBL] [Abstract][Full Text] [Related]
9. Alterations in novel candidate tumor suppressor genes, ING1 and ING2 in human lung cancer.
Okano T; Gemma A; Hosoya Y; Hosomi Y; Nara M; Kokubo Y; Yoshimura A; Shibuya M; Nagashima M; Harris CC; Kudoh S
Oncol Rep; 2006 Mar; 15(3):545-9. PubMed ID: 16465410
[TBL] [Abstract][Full Text] [Related]
10. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines.
Mitsudomi T; Viallet J; Mulshine JL; Linnoila RI; Minna JD; Gazdar AF
Oncogene; 1991 Aug; 6(8):1353-62. PubMed ID: 1679529
[TBL] [Abstract][Full Text] [Related]
11. The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern.
Takahashi T; Takahashi T; Suzuki H; Hida T; Sekido Y; Ariyoshi Y; Ueda R
Oncogene; 1991 Oct; 6(10):1775-8. PubMed ID: 1656362
[TBL] [Abstract][Full Text] [Related]
12. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis.
de Anta JM; Jassem E; Rosell R; Martínez-Roca M; Jassem J; Martínez-López E; Monzó M; Sánchez-Hernández JJ; Moreno I; Sánchez-Céspedes M
Oncogene; 1997 Dec; 15(24):2951-8. PubMed ID: 9416838
[TBL] [Abstract][Full Text] [Related]
13. p53 tumor suppressor gene mutation in early esophageal precancerous lesions and carcinoma among high-risk populations in Henan, China.
Gao H; Wang LD; Zhou Q; Hong JY; Huang TY; Yang CS
Cancer Res; 1994 Aug; 54(16):4342-6. PubMed ID: 8044781
[TBL] [Abstract][Full Text] [Related]
14. FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations.
Fong KM; Biesterveld EJ; Virmani A; Wistuba I; Sekido Y; Bader SA; Ahmadian M; Ong ST; Rassool FV; Zimmerman PV; Giaccone G; Gazdar AF; Minna JD
Cancer Res; 1997 Jun; 57(11):2256-67. PubMed ID: 9187130
[TBL] [Abstract][Full Text] [Related]
15. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
Huang C; Taki T; Adachi M; Konishi T; Higashiyama M; Miyake M
Oncogene; 1998 May; 16(19):2469-77. PubMed ID: 9627113
[TBL] [Abstract][Full Text] [Related]
16. Mutations of the p53 gene in human lung cancer from chromate-exposed workers.
Kondo K; Hino N; Sasa M; Kamamura Y; Sakiyama S; Tsuyuguchi M; Hashimoto M; Uyama T; Monden Y
Biochem Biophys Res Commun; 1997 Oct; 239(1):95-100. PubMed ID: 9345276
[TBL] [Abstract][Full Text] [Related]
17. Identification of intronic point mutations as an alternative mechanism for p53 inactivation in lung cancer.
Takahashi T; D'Amico D; Chiba I; Buchhagen DL; Minna JD
J Clin Invest; 1990 Jul; 86(1):363-9. PubMed ID: 2164047
[TBL] [Abstract][Full Text] [Related]
18. Genomic organization and mutation analysis of Hel-N1 in lung cancers with chromosome 9p21 deletions.
Cairns P; Okami K; King P; Bonacum J; Ahrendt S; Wu L; Mao L; Jen J; Sidransky D
Cancer Res; 1997 Dec; 57(23):5356-9. PubMed ID: 9393760
[TBL] [Abstract][Full Text] [Related]
19. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
[TBL] [Abstract][Full Text] [Related]
20. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation.
Bodner SM; Minna JD; Jensen SM; D'Amico D; Carbone D; Mitsudomi T; Fedorko J; Buchhagen DL; Nau MM; Gazdar AF
Oncogene; 1992 Apr; 7(4):743-9. PubMed ID: 1565469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
